VivoSeq
Infectious Disease

Hantavirus Pulmonary Syndrome

2

Pipeline Programs↗

0

Active Trials↗

0

Companies Involved↗

Hantavirus Pulmonary Syndrome is an early-stage landscape with 2 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Pipeline

Programs by Phase

Analysis

Modality Breakdown

2programs
Small molecule150%
Vaccine150%

Modality classified for 100% of 2 pipeline programs.

Analysis

Trial Status

2

clinical trials

Completed2 · 100%

Clinical Trials

Trial Activity

Andes Virus DNA Vaccine for the Prevention of Hantavirus Pulmonary Syndrome Using the PharmaJet Stratis(R) Needle-Free Injection Delivery Device
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT03682107·48 enrolled
A Collaborative Double-Blind Placebo-Controlled Trial of Intravenous Ribavirin As a Treatment for Presumed Hantavirus Pulmonary Syndrome
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001123·130 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)